Categories: News

Equillium to Host Conference Call Following Presentation of Data from the EQUATE Study in Acute Graft Versus Host Disease at the EHA2021 Virtual Congress of the European Hematology Association on June 11

Presentation and conference call will include topline data from all cohorts

The risk-benefit profile observed supports advancing development of itolizumab in first-line therapy

LA JOLLA, Calif.., June 03, 2021 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will host a conference call on Friday, June 11, 2021, at 8:00 am ET, following an oral presentation of data from the EQUATE study of itolizumab in acute graft-versus-host disease (aGVHD) at EHA2021 Virtual Congress.

Presenters include:

  • Dolca Thomas, M.D., Chief Medical Officer
  • Steve Connelly, Ph.D., Chief Scientific Officer
  • Bruce Steel, Chief Executive Officer

The presentations will be followed by Q&A with management.

Details for the conference call will be provided the morning of Friday, June 11. A live webcast of the event will be available on the company’s website and a replay will be available for 90 days on the Events & Presentations page of the Investor Relations section of the company’s website at https://ir.equilliumbio.com/events-and-presentations.

About Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.
For more information, visit www.equilliumbio.com.

Investor Contact
Michael Moore
Vice President, Investor Relations & Corporate Communications
619-302-4431
ir@equilliumbio.com

Media Contacts
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

Staff

Recent Posts

BioHarvest Sciences Reports Third Quarter 2024 Financial Results

Third Quarter 2024 Revenue Increased 101% Year-over-Year to Over $6.5 Million, Exceeding Management GuidanceVancouver, British…

50 minutes ago

Juva Life Inc. Updates Shareholders on Court-Appointed Receivership Proceedings

REDWOOD CITY, CA / ACCESSWIRE / November 25, 2024 / Juva Life Inc. (CSE:JUVA)(OTC PINK:JUVAF)(FRANKFURT:4VV)…

3 hours ago

Ankle & Foot Centers of America Highlights Vital Role of Podiatric Care for People with Diabetes

During National Diabetes Awareness Month, the major multi-state podiatry group emphasizes how its advanced vascular…

3 hours ago

Hemostemix Announces ACP-01 Treatment-Purchase Available with Social Media Campaign Underway

Calgary, Alberta--(Newsfile Corp. - November 25, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE:…

4 hours ago

Maverick Medical AI, NewVue.ai, and RADPAIR Announce Strategic Integration to Reduce Burnout and Optimize Financial Performance

Real-Time Revenue Cycle Management and Clinical Workflow Optimization for Radiology Practices to Debut at RSNA…

6 hours ago

Cortechs.ai Partners with Mermaid Beach Radiology to Bring Precision AI Imaging Solutions to Their MRI and CT Services

SAN DIEGO, Nov. 25, 2024 /PRNewswire/ -- Cortechs.ai, a leading provider of AI-powered imaging solutions,…

6 hours ago